Baiyunshan's aggregated accounts receivable disposal becomes disclosable transaction

Guangzhou Baiyunshan Pharmaceutical Holdings has confirmed the sale of its fourth batch of new underlying assets to Everbright Asset Management, receiving a purchase price of RMB501,956,830.93 on August 28, 2025. This transaction, individually, does not constitute a disclosable transaction as the applicable percentage ratios are below 5%.

However, when aggregated with prior related transactions over 12 months, the combined maximum applicable percentage ratio for these transactions falls between 5% and 25%. Consequently, this makes the overall disposal of accounts receivable a disclosable transaction under Chapter 14 of the Listing Rules, requiring reporting and announcement but not shareholder approval.

The total book value of accounts receivable across these aggregated transactions amounts to RMB3,051,222,778.70, with Guangzhou Pharmaceutical receiving a total purchase price of RMB3,010,537,989.64. The difference of approximately RMB0.41 bn will cover financing costs and related taxes, with net proceeds supplementing Guangzhou Pharmaceutical's working capital.